| Administration route |
intravenous infusion |
| Dosage |
2.5E6 cells, 12.5E6 cells, 25E6 cells, 40E6 cells |
| Donor type |
Autologous |
| Pts |
47 |
| Age |
Adult, Older_Adult |
| Outcome |
65%(CR,DL2).96% of patients reported any-grade adverse events, and 89% had grade ≥3 events. CRS occurred in 33% of patients, managed with tocilizumab, corticosteroids, and vasopressors. ICANS occurred in 11% of patients, with management involving dexamethasone, methylprednisolone, and anakinra. |
| Adverse reactions |
All patients reported 1 any-grade adverse event; 96% had ≥1 event of grade ≥3. Sixteen patients(34%) experienced cytokine release syndrome(CRS; 1 grade-4 event). DL2 median time to CRS onset, 8 days(range, 1–17 days); median time to resolution, 6 days(range, 2–25 days). |
| References |
DOI:
10.1016/S2152-2650(23)01520-3
|
|